VIVOLTA today announced key appointments to its leadership team as part of its commitment to driving innovation and continued growth.
New CEO to Lead Strategic Initiatives:
Denis Leissing has been appointed as the new Chief Executive Officer (CEO), taking over from Ramon Solberg, who held the position ad interim since 2022. Mr. Leissing brings decades of international experience in the medical device and contract manufacturing sectors, with a proven track record of successfully leading organizations through transformative, high-growth phases. In his previous role as CEO of Mediliant, a Swiss medical device manufacturing organization serving the world’s largest medical device brands, Mr. Leissing demonstrated a keen understanding of the global medical device industry and trends, while effectively leading the company to fulfill its vision – one similar to VIVOLTA’s aim to be the trusted partner in contract development and manufacturing of electrospun medical products. Mr. Leissing holds a master’s degree in mechanical engineering from ECAM Lyon, and an executive Master of business administration from HEC Paris.
Mr. Solberg, founder of the company, will continue to lead VIVOLTA’s technology initiatives as Chief Technology Officer.
Non-Executive Chairman of the Board Appointment:
VIVOLTA has also appointed Rudy Mareel as the new Non-Executive Chairman of the Board, succeeding Fennemiek Gommer in this role. Mr. Mareel is a seasoned executive in the healthcare industry, bringing a wealth of expertise and experience to his new role at VIVOLTA. With a distinguished career in senior leadership roles in both Europe and the US, along with an in-depth understanding of the global healthcare market, he led Polyganics, a Dutch regenerative medicine company, to a successful acquisition by Regenity Biosciences (formerly Collagen Matrix) last year. With his extensive experience serving on both Executive and Non-Executive boards to various healthcare companies, he will play a pivotal role in guiding VIVOLTA’s Board of Directors and supporting the company’s strategic initiatives. He takes on the role from Ms. Gommer who held the position of Chairman since 2021, guiding the transition of VIVOLTA from an electrospinning equipment supplier (formerly known as IME Medical Electrospinning) into a contract development and manufacturing organization.
These leadership changes come at a pivotal moment for VIVOLTA, following the recent successful funding round of €7 million supported by existing shareholders TIIN Capital, 819 Capital Partners (formerly Lumana Invest), Borski Fund, and Brabantse Ontwikkelings Maatschappij, as well as the Dutch government’s NXTGEN HIGHTECH growth fund. The funds are being used to further advance VIVOLTA’s plans to transform its clients’ development projects into fully scalable commercial products over the coming years.Read the full press release here